ArriVent's Lead Drug Fails Phase 3 Primary Endpoint in First-Line Lung Cancer
AVBP sits 69% above its 52-week low of $17.
Summary
ArriVent's pivotal Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary PFS endpoint by blinded independent central review. Secondary endpoints showed clinical benefit and overall survival trended favorably but remains immature; safety was consistent with prior data. This is a major setback for the company's lead asset, which had been positioned for first-line approval in this indication. The miss threatens the first-line path and the valuation tied to it, though the immature OS trend and secondary benefits may support alternative development strategies. The company is evaluating its development path, which could lead to pipeline reprioritization and changes in spend and timelines. This follows the 8-K filed earlier today disclosing the same trial failure, but this news adds the market's interpretation and the specific endpoint details.
At the time of this announcement, AVBP was trading at $28.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.00 to $35.83. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.